The intramuscular method is chosen for its effectiveness in delivering the dose directly into the muscle
For those seeking comprehensive and specialized care in managing tinnitus, Treble Healths audiologists have decades of experience in treating tinnitus
Is imaging guidance included
Each batch undergoes independent analytical testing to verify: Compound identity Assay accuracy Purity confirmation Microbial safety Endotoxin levels Heavy metal screening Full batch traceability Research Use Limitation Used solely for in vitro experiments Not permitted for clinical trials involving humans Not permitted for human or veterinary administration Not permitted for investigational human use Independently analysed by Liquilabs s.r.o

Mechanism of Action Upregulates actin binding proteins , accelerating cellular repair and regeneration Promotes angiogenesis (new blood vessel growth) for improved tissue oxygenation Reduces pro-inflammatory cytokines Improves cell mobility , enabling faster healing of ligaments and soft tissue Enhances muscle recovery and flexibility after trauma or intense training Thymosin Beta4 and its synthetic analog TB500 exhibit potent tissue regeneration effects by modulating cellular migration, angiogenesis, and inflammatory balance. Huff et al., Annals of the New York Academy of Sciences Applications Chronic joint pain, tendinopathy, or ligament injuries Muscle tears, strains, or post-surgical recovery Circulatory improvements in damaged or under-perfused tissue Often stacked with: BPC157 for gut, tendon, and ligament healing CJC1295 for hormonal support and sleep recovery MK677 for long-term IGF1 support Delivery Injected subcutaneously or intramuscularly , depending on location of injury Typical dosing: 25 mg per week , divided into 23 doses Loading phase: 46 weeks Maintenance phase: 23 mg weekly as needed Benefits Breakdown: BPC157 vs MK677 vs CJC1295 vs TB500 To fully understand the strengths of each peptide, heres a breakdown of their primary performance and recovery benefits , based on clinical studies and real-world usage in bodybuilding, injury rehab, and hormone optimization

Injectable GHK-Cu was removed from FDA Category 2 on April 15, 2026